【机构调研记录】恒生前海基金调研心脉医疗

Group 1 - The core viewpoint of the news is that Hengsheng Qianhai Fund has conducted research on a listed company, focusing on its financial performance and product developments [1] - The company, Xinmai Medical, reported a revenue of 714 million yuan and a net profit of 315 million yuan during the reporting period [1] - The company plans to distribute a cash dividend of 1.57 billion yuan, which is 13.00 yuan per 10 shares (including tax) [1] - The product Cratos was launched domestically in March with a listing price below 100,000 yuan, and its promotion progress has exceeded expectations [1] - Hector has received a custom certificate from the EU and has completed clinical implants in multiple European countries, gaining recognition from doctors [1] - The company's R&D investment is expected to be around 10% this year, with a future target of maintaining it between 10% and 15% [1] - Overseas revenue has increased by over 95% year-on-year, accounting for 17% of total revenue, primarily due to the consolidation of Lombard and organic growth, covering 45 countries with plans to expand to 60 countries next year [1] - High-margin products such as Talos, Cratos, and Fontus are set to be launched internationally [1] Group 2 - Hengsheng Qianhai Fund was established in 2016 and currently has an asset management scale of 16.47 billion yuan, ranking 126 out of 210 [2] - The fund's asset management scale for non-monetary public funds is 16.468 billion yuan, ranking 109 out of 210 [2] - The fund manages 54 public funds, ranking 100 out of 210, with 7 fund managers, ranking 126 out of 210 [2] - The best-performing public fund product in the past year is Hengsheng Qianhai High-end Manufacturing Mixed A, with a latest net value of 0.96 and a growth of 89.37% over the past year [2] - The latest public fund product raised by the fund is Hengsheng Qianhai Ruifeng Mixed A, which is a mixed-type equity fund, with a concentrated subscription period from August 18, 2025, to September 5, 2025 [2]